Coramaze raises €4.5m from HTGF et al.

Previous backers High-Tech Gründerfonds (HTGF) and Seed Capital Dortmund, as well as private investors, took part in the round.

The fresh capital will be used for the company's first clinical study in humans in 2016 and a subsequent feasibility trial.

HTGF focuses on high-tech startups. It typically invests €500,000 at the seed stage, with the potential for up to a total of €2m in follow-on financing.

Seed Capital Dortmund also focuses on high-tech startups and invests a maximum of €500,000 at the seed stage. It can provide an additional €1.5m in further rounds.

Previous funding
HTGF led Coramaze's €1m seed round in February 2014, along with Seed Capital Dortmund.

Company
Founded in 2013, Coramaze is a developer of medical devices for the treatment of heart valve diseases. The firm is based in Munich, Germany.

People
Laura Figulla is co-founder and CEO of Coramaze. Ari Bronshtein is CEO of Elron Electronic Industries. Christian Jung is senior investment manager at HTGF.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• High-Tech Gründerfonds